- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07784855
Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
WVU011625: The Role of Scheduled Intravenous Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. Many of these toxicities may be exacerbated by dehydration and are commonly managed with clinician-directed intravenous (IV) hydration. This study will evaluate whether scheduled IV hydration reduces the incidence and severity of treatment-related toxicities compared with clinician assessment-based hydration. Participants will be randomized 1:1 to scheduled IV hydration or clinician assessment-based IV hydration beginning in Week 3 of concurrent chemoradiotherapy and continuing through one week following completion of chemoradiotherapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Nina Moore
- Número de teléfono: 304-293-2991
- Correo electrónico: nina.moore@hsc.wvu.edu
Copia de seguridad de contactos de estudio
- Nombre: Ella Betler
- Número de teléfono: 304-293-4273
- Correo electrónico: eibetler@hsc.wvu.edu
Ubicaciones de estudio
-
-
West Virginia
-
Bridgeport, West Virginia, Estados Unidos, 26330
- Aún no reclutando
- WVU Medicine United Hospital Center
-
Contacto:
- Sabrina Rexroad
- Número de teléfono: 681-342-1000
- Correo electrónico: sabrina.rexroad1@wvumedicine.org
-
Martinsburg, West Virginia, Estados Unidos, 25401
- Aún no reclutando
- WVU Medicine Berkeley Medical Center
-
Contacto:
- Valli White
- Número de teléfono: 304-264-1220
- Correo electrónico: valli.white@wvumedicine.org
-
Morgantown, West Virginia, Estados Unidos, 26506
- Reclutamiento
- West Virginia University Cancer Institute
-
Contacto:
- Nina Moore
- Número de teléfono: 304-293-2991
- Correo electrónico: nina.moore@hsc.wvu.edu
-
Investigador principal:
- David Clump, MD, PhD
-
Investigador principal:
- Sidra Najeeb, MD
-
Contacto:
- Ella Betler
- Número de teléfono: 304-293-4273
- Correo electrónico: eibetler@hsc.wvu.edu
-
Parkersburg, West Virginia, Estados Unidos, 26101
- Aún no reclutando
- WVU Medicine Camden Clark Medical Center
-
Contacto:
- Layla Tannaoury
- Número de teléfono: 304-424-2585
- Correo electrónico: Layla.tannoury@wvumedicine.org,
-
Princeton, West Virginia, Estados Unidos, 24740
- Aún no reclutando
- WVU Medicine Princeton Community Hospital
-
Contacto:
- Melissa Boggess
- Número de teléfono: 304-487-7515
- Correo electrónico: melissa.boggess1@wvumedicine.org
-
Wheeling, West Virginia, Estados Unidos, 26003
- Aún no reclutando
- WVU Medicine Wheeling Hospital
-
Contacto:
- Maher Kali
- Número de teléfono: 304-243-7045
- Correo electrónico: maher.kali@wvumedicine.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ECOG 0-2
- Non-nasopharyngeal squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx primary
- Planned for concurrent chemoradiotherapy (CCRT) with standard-of-care cisplatin-based regimen (IV cisplatin 100mg/m2 once every three weeks for up to three doses or IV cisplatin 40mg/m2 weekly) with concurrent radiotherapy (treatment duration approximately 6-7 weeks, per institutional standards).
- The use of immunotherapy in combination with CCRT is permitted and does not affect eligibility or group assignment.
Exclusion Criteria:
- Nasopharyngeal squamous cell carcinomas, nasal cavity and paranasal sinus squamous cell carcinomas.
- History of congestive heart failure.
- Dependency on enteral nutrition and hydration prior to enrollment.
- Use of diuretics that cannot be safely held during study treatment (participants who are able to temporarily discontinue diuretics during treatment are eligible).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Scheduled IV Hydration
Participants will receive scheduled IV hydration approximately twice per week throughout the treatment period. IV fluids will continue even if chemoradiotherapy infusion is held due to toxicities or cytopenias. |
Normal saline (0.9% sodium chloride) 1L of saline will be administered at each hydration visit. Participants will receive IV fluids on a planned schedule of twice a week, starting in Week 3 of chemoradiation treatment and continuing for one week after treatment is completed. |
|
Otro: Clinician Assessment-Based IV Hydration
Participants will receive IV fluids (normal saline) only as clinically indicated and ordered by their treating clinician, per standard of care. IV fluids may continue if chemoradiotherapy infusion is held due to toxicities or cytopenias, at the discretion of the treating clinician. |
IV fluids (normal saline (0.9% sodium chloride)) only as clinically indicated and ordered by their treating clinician, per standard of care. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of at least one Grade ≥3 Treatment-Related Toxicities of Interest
Periodo de tiempo: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of participants experiencing at least one Grade ≥3 according to National Cancer Institute Common Terminology Criteria for Adverse Events v6.0 (NCI CTCAE) treatment-related toxicity of interest, including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, or trismus, during concurrent chemoradiotherapy. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidences of Individual Treatment-Related Toxicities of Interest
Periodo de tiempo: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of treatment-related mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus of any grade, as assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
|
Incidence of Enteric Tube Placement
Periodo de tiempo: From initiation of treatment through 6 months after completion of chemoradiotherapy
|
Incidence of participants requiring enteric feeding tube placement during treatment and follow-up. |
From initiation of treatment through 6 months after completion of chemoradiotherapy
|
|
Incidence of Hematologic Toxicities
Periodo de tiempo: Weeks 3-6 of concurrent chemoradiotherapy
|
Incidence of leukopenia, anemia, and thrombocytopenia assessed during weeks 3-6 of concurrent chemoradiotherapy treatment as assessed according to NCI CTCAE v6.0. |
Weeks 3-6 of concurrent chemoradiotherapy
|
|
Residual Grade of Toxicities of Interest at 3 Months
Periodo de tiempo: 3 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Residual grade of Toxicities of Interest at 6 Months
Periodo de tiempo: 6 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 3 Months
Periodo de tiempo: 3 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 6 Months
Periodo de tiempo: 6 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sidra Najeeb, MD, WVU Cancer Center
- Silla de estudio: David Clump, MD, PhD, WVU Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00000501
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data collected during the study, including demographic information, eligibility criteria, treatment/exposure data, outcome assessments, and relevant follow-up data, will be made available to qualified researchers. Data that could directly identify participants will not be shared.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .